A detailed history of Dimensional Fund Advisors LP transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 905,736 shares of SWTX stock, worth $34.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
905,736
Previous 968,405 6.47%
Holding current value
$34.2 Million
Previous $35.3 Million 26.12%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$36.5 - $52.5 $2.29 Million - $3.29 Million
-62,669 Reduced 6.47%
905,736 $44.6 Million
Q4 2023

Feb 07, 2024

SELL
$18.94 - $37.24 $813,738 - $1.6 Million
-42,964 Reduced 4.25%
968,405 $35.3 Million
Q3 2023

Nov 09, 2023

BUY
$23.12 - $31.38 $647,729 - $879,142
28,016 Added 2.85%
1,011,369 $23.4 Million
Q2 2023

Aug 09, 2023

BUY
$23.15 - $32.71 $4.35 Million - $6.15 Million
187,890 Added 23.62%
983,353 $25.8 Million
Q1 2023

May 12, 2023

BUY
$24.97 - $34.05 $13 Million - $17.8 Million
522,571 Added 191.49%
795,463 $20.5 Million
Q4 2022

Feb 09, 2023

BUY
$21.73 - $28.72 $3.93 Million - $5.2 Million
181,050 Added 197.13%
272,892 $7.1 Million
Q3 2022

Nov 10, 2022

SELL
$24.1 - $39.66 $1.47 Million - $2.43 Million
-61,158 Reduced 39.97%
91,842 $2.62 Million
Q2 2022

Aug 12, 2022

SELL
$18.36 - $60.07 $781,016 - $2.56 Million
-42,539 Reduced 21.75%
153,000 $3.77 Million
Q1 2022

May 13, 2022

BUY
$48.97 - $65.46 $161,405 - $215,756
3,296 Added 1.71%
195,539 $11 Million
Q4 2021

Feb 09, 2022

SELL
$53.3 - $75.84 $191,506 - $272,493
-3,593 Reduced 1.83%
192,243 $11.9 Million
Q3 2021

Nov 12, 2021

BUY
$62.66 - $88.26 $7.54 Million - $10.6 Million
120,323 Added 159.34%
195,836 $12.4 Million
Q2 2021

Aug 12, 2021

BUY
$67.45 - $85.63 $5.09 Million - $6.47 Million
75,513 New
75,513 $6.22 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.36B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.